LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Cyt ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period from November 30, 2023, to July 3, 2025, alleging misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Jasper Therapeutics lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, particularly briquilimab [5]. - It is alleged that the company's public statements were materially false and misleading, leading to investor damages when the true details were revealed [5]. Group 2: Participation Information - Investors who purchased Jasper Therapeutics securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its manufacturing controls and clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 30, 2023, to July 3, 2025, with a deadline for lead plaintiff appointments set for November 18, 2025 [2]. - The complaint alleges that Jasper Therapeutics made false and misleading statements, particularly regarding its controls over third-party manufacturing and the risks posed to its clinical trials due to manufacturing partner issues [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to participate [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Jasper Therapeutics, Inc. on behalf of investors who acquired its securities during the specified class period [1] Group 1 - The lawsuit is initiated by Glancy Prongay & Murray LLP, a prominent national shareholder rights law firm [1] - The class period for the lawsuit is defined as from November 30, 2023, to July 3, 2025 [1] - Investors have until November 18, 2025, to file a lead plaintiff motion [1]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of federal securities laws during the defined class period [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Jasper securities between November 30, 2023, and July 3, 2025 [2]. Case Details - The Complaint alleges that Jasper made materially false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - Heightened likelihood of disruptive cost-reduction measures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Defendants' statements regarding the Company's operations and prospects were materially false and misleading [3]. Next Steps - Interested parties can review the Complaint and have until November 18, 2025, to request appointment as lead plaintiff [4]. Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Jasper and its executives made false statements regarding the company's manufacturing controls and the implications for its product, briquilimab [6][7]. Group 2: Company Performance and Stock Impact - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [7]. - The company announced a halt in the development of briquilimab for asthma and SCID, contradicting previous claims of a strong financial position [7].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - PepGen Inc. (PEPG) is up 151% at $6.68 [3] - 22nd Century Group, Inc. (XXII) is up 27% at $1.93 [3] - Immuneering Corporation (IMRX) is up 23% at $11.36 [3] - uniQure N.V. (QURE) is up 10% at $52.58 [3] - Lithium Americas Corp. (LAC) is up 9% at $6.60 [3] - Jasper Therapeutics, Inc. (JSPR) is up 9% at $2.55 [3] - American Shared Hospital Services (AMS) is up 8% at $2.75 [3] - PSQ Holdings, Inc. (PSQH) is up 7% at $3.06 [3] - K Wave Media Ltd. (KWM) is up 7% at $2.48 [3] - ClearPoint Neuro, Inc. (CLPT) is up 5% at $20.48 [3] Premarket Losers - Transocean Ltd. (RIG) is down 14% at $3.11 [4] - Cyclerion Therapeutics, Inc. (CYCN) is down 12% at $2.83 [4] - CarMax, Inc. (KMX) is down 11% at $50.38 [4] - ARB IOT Group Limited (ARBB) is down 11% at $10.45 [4] - SHF Holdings, Inc. (SHFS) is down 10% at $6.49 [4] - Digital Brands Group, Inc. (DBGI) is down 10% at $6.21 [4] - Aqua Metals, Inc. (AQMS) is down 9% at $5.29 [4] - Akanda Corp. (AKAN) is down 8% at $3.96 [4] - Galecto, Inc. (GLTO) is down 8% at $3.88 [4] - Platinum Analytics Cayman Limited (PLTS) is down 7% at $11.12 [4]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which could affect the clinical trial results and the commercial viability of its products [2]. - Specific allegations include the lack of necessary controls for third-party manufacturers, increasing the risk of confounded study results, and overstating the company's financial and clinical prospects [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by November 18, 2025, although participation is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].

Group 1 - A class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. securities between November 30, 2023, and July 3, 2025 [1] - Investors have until November 18, 2025, to file a lead plaintiff motion [1] - The lawsuit is related to losses suffered by investors in Jasper Therapeutics, Inc. [1]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging investors of Jasper Therapeutics, Inc. (JSPR) to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking investors who may have been affected by the alleged securities fraud involving Jasper Therapeutics [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications for investors [1] - This action reflects broader issues within the biotechnology sector, where companies may face scrutiny over their financial disclosures and operational transparency [1]